Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Corcept Therapeutics clinical trials
The registry lists 73 studies whose lead sponsor is Corcept Therapeutics. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 16, 2026.
Keep track of what changes. Save the Corcept Therapeutics studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Corcept Therapeutics.
- Corcept Therapeutics73 studiesSame company
Something wrong?
Focus areas
Conditions Corcept Therapeutics leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 73. Browse all 73 →
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingNCT07259317Phase 2
- Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesRecruitingNCT07276373Phase 1/2
- Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersRecruitingNCT06906341Phase 2
- Evaluating the Pharmacokinetics and Safety of MiricorilantCompletedNCT07553663Phase 1
- Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeActive, not recruitingNCT03604198Phase 2
- Evaluation of Miricorilant on Liver Fat in Patients With MASLDCompletedNCT06947304Phase 1
- A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)CompletedNCT06108219Phase 2
- Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerActive, not recruitingNCT05257408Phase 3
- Dazucorilant in Patients With Amyotrophic Lateral SclerosisActive, not recruitingNCT05407324Phase 2
- Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate CancerTerminatedNCT03437941Phase 1/2
- Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult SubjectsCompletedNCT07240116Phase 1
- Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)CompletedNCT06829537
- Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT03776812Phase 2
- A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal AdenomasCompletedNCT04308590Phase 3
- A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromeCompletedNCT03697109Phase 3
- Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult ParticipantsCompletedNCT06495944Phase 1
- Effects of Hepatic Impairment on the Pharmacokinetics of DazucorilantCompletedNCT06928779Phase 1
- Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of MiricorilantCompletedNCT05553470Phase 1
- Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)CompletedNCT05772169Phase 4
- A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic MedicationsCompletedNCT03818256Phase 2
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)CompletedNCT05117489Phase 1
- A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)CompletedNCT05320146
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)CompletedNCT04524403Phase 2
- Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)CompletedNCT04373265Phase 1
- Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal AdenocarcinomaTerminatedNCT04329949Phase 3
- A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of RelacorilantCompletedNCT06094725Phase 1
- A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male SubjectsCompletedNCT06094712Phase 1
- A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy SubjectsCompletedNCT06094738Phase 1
- A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy SubjectsCompletedNCT06094790Phase 1
- Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's SyndromeCompletedNCT02663609
- Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of MiricorilantCompletedNCT05712265Phase 1
- Single and Multiple Ascending Dose Study of CORT125236 in Healthy ParticipantsCompletedNCT05003713Phase 1
- Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy ParticipantsCompletedNCT05347979Phase 1
- Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid TumorsCompletedNCT02762981Phase 1/2
- Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)TerminatedNCT03823703Phase 2
- Single and Multiple Ascending Dose Study of CORT125329 in Healthy ParticipantsCompletedNCT04672512Phase 1
- A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male VolunteersCompletedNCT00698022Phase 1
- Single and Multiple Ascending Dose Study of CORT113176 in Healthy ParticipantsCompletedNCT04249323Phase 1
- Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male ParticipantsCompletedNCT04990310Phase 1
- Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy ParticipantsCompletedNCT04994743Phase 1
- T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy VolunteersCompletedNCT04795479Phase 1
- Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy ParticipantsCompletedNCT04672499Phase 1
- The Effect of CORT118335 on Olanzapine-Induced Weight GainCompletedNCT03877562Phase 1
- Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its MetabolitesCompletedNCT03512548Phase 1
- Study to Evaluate CORT125134 in Participants With Cushing's SyndromeCompletedNCT02804750Phase 2
- A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the BodyCompletedNCT03067376Phase 1
- CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)CompletedNCT03508635Phase 1
- Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing SyndromeTerminatedNCT03379363
- Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male ParticipantsCompletedNCT03878264Phase 1
- First-in-human Study in Healthy SubjectsCompletedNCT03315338Phase 1